It is interesting that getting naive patients for
Post# of 148181
(Total Views: 380)
Posted On: 01/10/2020 12:27:37 PM
It is interesting that getting naive patients for inclusion in the mtnbc trial is not that important, getting as many cancer patients as possible is. I think any partner is looking at the data as a whole and the FDA trial and approval as not a problem. The 25-30 patients that want this drug for their cancer is great for us, mostly for them!
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼